Background Pheochromocytoma is a feature of two disorders withan autosomal dominant pattern of inheritance -- multiple endocrineneoplasia type 2 (MEN-2) (with medullary thyroid carcinoma andhyperparathyroidism) and von Hippel-Lindau disease (with angiomaof the retina, hemangioblastoma of the central nervous system,renal-cell carcinoma, pancreatic cysts, and epididymal cystadenoma).The frequency of these syndromes in patients with pheochromocytomais not known.
Methods In an unselected group of patients with pheochromocytoma,we performed pentagastrin tests, parathyroid hormone assays,computed tomography (CT) or magnetic resonance imaging (MRI)of the brain, ophthalmoscopy, CT imaging of the abdomen, andultrasonography of the testes. We also screened members of familieswith MEN-2 or von Hippel-Lindau disease for pheochromocytomaby measuring plasma and urine catecholamines and plasma chromograninA and by performing abdominal ultrasonography, CT and MRI, andmetaiodobenzylguanidine scintigraphy.
Results Nineteen of 82 unselected patients with pheochromocytomas(23 percent) were carriers of familial disorders; 19 percenthad von Hippel-Lindau disease and 4 percent had MEN-2. Prospectively,in 36 of 79 subjects at risk for pheochromocytoma (46 percent),42 unsuspected pheochromocytomas were found. Overall, therewere 130 patients with 185 pheochromocytomas; 43 had von Hippel-Lindaudisease, 24 had MEN-2, and 63 had sporadic tumors. The patientswith familial and those with sporadic pheochromocytomas differedin mean age at diagnosis (32 vs. 46 years, P<0.001), multifocallocalization (55 vs. 8 percent, P<0.001), and cancer (0 vs.11 percent, P = 0.005); but not in the frequency of extraadrenaltumors (24 vs. 16 percent). Thirty-eight percent of carriersof von Hippel-Lindau disease and 24 percent of carriers of MEN-2had pheochromocytoma as the only manifestation of their syndrome.
Conclusions All patients with pheochromocytomas should be screenedfor MEN-2 and von Hippel-Lindau disease to avert further morbidityand mortality in the patients and their families. All patientsin families with MEN-2 or von Hippel-Lindau disease should bescreened for pheochromocytoma, even if they are asymptomatic.
Source Information
From the Departments of Medicine (H.P.H.N., D.P.B., B.V.), Radiology (G.S., U.B.), Ophthalmology (D.S.), and Surgery (G.K.), Albert-Ludwigs-Universitat, Freiburg, Germany; and the Department of Medicine, University of California, San Diego (R.J.P.).
Address reprint requests to Dr. Neumann at the Division of Nephrology and Hypertension, University of Freiburg, Hugstetterstr. 55, D-79106 Freiburg im Breisgau, Germany.
Gergics, P., Patocs, A., Toth, M., Igaz, P., Szucs, N., Liko, I., Fazakas, F., Szabo, I., Kovacs, B., Glaz, E., Racz, K.
(2009). Germline VHL gene mutations in Hungarian families with von Hippel-Lindau disease and patients with apparently sporadic unilateral pheochromocytomas. Eur J Endocrinol
161: 495-502
[Abstract][Full Text]
Srirangalingam, U., Khoo, B., Walker, L., MacDonald, F., Skelly, R. H, George, E., Spooner, D., Johnston, L. B, Monson, J. P, Grossman, A. B, Drake, W M, Akker, S. A, Pollard, P. J, Plowman, N., Avril, N., Berney, D. M, Burrin, J. M, Reznek, R. H, Kumar, V K A., Maher, E. R, Chew, S. L
(2009). Contrasting clinical manifestations of SDHB and VHL associated chromaffin tumours. Endocr Relat Cancer
16: 515-525
[Abstract][Full Text]
Yuan, W., Wang, W., Cui, B., Su, T., Ge, Y., Jiang, L., Zhou, W., Ning, G.
(2008). Overexpression of ERBB-2 was more frequently detected in malignant than benign pheochromocytomas by multiplex ligation-dependent probe amplification and immunohistochemistry. Endocr Relat Cancer
15: 343-350
[Abstract][Full Text]
Boyle, J. G., Davidson, D. F., Perry, C. G., Connell, J. M. C.
(2007). Comparison of Diagnostic Accuracy of Urinary Free Metanephrines, Vanillyl Mandelic Acid, and Catecholamines and Plasma Catecholamines for Diagnosis of Pheochromocytoma. J. Clin. Endocrinol. Metab.
92: 4602-4608
[Abstract][Full Text]
d'Herbomez, M., Forzy, G., Bauters, C., Tierny, C., Pigny, P., Carnaille, B., Pattou, F., Wemeau, J.-L., Rouaix, N.
(2007). An analysis of the biochemical diagnosis of 66 pheochromocytomas. Eur J Endocrinol
156: 569-575
[Abstract][Full Text]
Chew, F. S., Banks, K. P.
(2006). Imaging of Pheochromocytoma and Incidental Adrenal Lesions: Self-Assessment Module. Am. J. Roentgenol.
187: S467-S469
[Abstract][Full Text]
Jimenez, C., Cote, G., Arnold, A., Gagel, R. F.
(2006). Should Patients with Apparently Sporadic Pheochromocytomas or Paragangliomas be Screened for Hereditary Syndromes?. J. Clin. Endocrinol. Metab.
91: 2851-2858
[Abstract][Full Text]
Sullivan, J., Groshong, T., Tobias, J. D.
(2005). Presenting Signs and Symptoms of Pheochromocytoma in Pediatric-aged Patients. CLIN PEDIATR
44: 715-719
[Abstract]
Neumann, H. P. H., Pawlu, C., Peczkowska, M., Bausch, B., McWhinney, S. R., Muresan, M., Buchta, M., Franke, G., Klisch, J., Bley, T. A., Hoegerle, S., Boedeker, C. C., Opocher, G., Schipper, J., Januszewicz, A., Eng, C., for the European-American Paraganglioma Study Grou,
(2004). Distinct Clinical Features of Paraganglioma Syndromes Associated With SDHB and SDHD Gene Mutations. JAMA
292: 943-951
[Abstract][Full Text]
Kaltsas, G. A., Besser, G. M., Grossman, A. B.
(2004). The Diagnosis and Medical Management of Advanced Neuroendocrine Tumors. Endocr. Rev.
25: 458-511
[Abstract][Full Text]
Bryant, J., Farmer, J., Kessler, L. J., Townsend, R. R., Nathanson, K. L.
(2003). Pheochromocytoma: The Expanding Genetic Differential Diagnosis. JNCI J Natl Cancer Inst
95: 1196-1204
[Abstract][Full Text]
Bravo, E. L., Tagle, R.
(2003). Pheochromocytoma: State-of-the-Art and Future Prospects. Endocr. Rev.
24: 539-553
[Abstract][Full Text]
Taupenot, L., Harper, K. L., O'Connor, D. T.
(2003). The Chromogranin-Secretogranin Family. NEJM
348: 1134-1149
[Full Text]
Koch, C. A., Pacak, K., Chrousos, G. P.
(2002). The Molecular Pathogenesis of Hereditary and Sporadic Adrenocortical and Adrenomedullary Tumors. J. Clin. Endocrinol. Metab.
87: 5367-5384
[Abstract][Full Text]
Baysal, B E
(2002). Hereditary paraganglioma targets diverse paraganglia. J. Med. Genet.
39: 617-622
[Abstract][Full Text]
Kashyap, A S, Kashyap, S
(2002). von Hippel-Lindau disease complicated by pheochromocytoma. Postgrad. Med. J.
78: 443-443
[Full Text]
Baghai, M., Thompson, G. B., Young, W. F. Jr, Grant, C. S., Michels, V. V., van Heerden, J. A.
(2002). Pheochromocytomas and Paragangliomas in von Hippel-Lindau Disease: A Role for Laparoscopic and Cortical-Sparing Surgery. Arch Surg
137: 682-689
[Abstract][Full Text]
Neumann, H. P., Bausch, B., McWhinney, S. R., Bender, B. U., Gimm, O., Franke, G., Schipper, J., Klisch, J., Altehoefer, C., Zerres, K., Januszewicz, A., Smith, W. M., Munk, R., Manz, T., Glaesker, S., Apel, T. W., Treier, M., Reineke, M., Walz, M. K., Hoang-Vu, C., Brauckhoff, M., Klein-Franke, A., Klose, P., Schmidt, H., Maier-Woelfle, M., Peczkowska, M., Szmigielski, C., Eng, C., the Freiburg-Warsaw-Columbus Pheochromocytoma Stud,
(2002). Germ-Line Mutations in Nonsyndromic Pheochromocytoma. NEJM
346: 1459-1466
[Abstract][Full Text]
Dluhy, R. G.
(2002). Pheochromocytoma -- Death of an Axiom. NEJM
346: 1486-1488
[Full Text]
Weise, M., Merke, D. P., Pacak, K., Walther, M. M., Eisenhofer, G.
(2002). Utility of Plasma Free Metanephrines for Detecting Childhood Pheochromocytoma. J. Clin. Endocrinol. Metab.
87: 1955-1960
[Abstract][Full Text]
Neumann, H. P.H., Reincke, M., Eng, C., Conlin, P. R.
(2001). Case 13-2001: Genetic Testing in Pheochromocytoma. NEJM
345: 547-548
[Full Text]
d'Herbomez, M., Gouze, V., Huglo, D., Nocaudie, M., Pattou, F., Proye, C., Wemeau, J.-L., Marchandise, X.
(2001). Chromogranin A Assay and 131I-MIBG Scintigraphy for Diagnosis and Follow-Up of Pheochromocytoma. JNM
42: 993-997
[Abstract][Full Text]
Maxwell, P. H., Buckley, C., Gleadle, J. M., Mason, P. D.
(2001). Nasty shock after an anti-emetic. Nephrol Dial Transplant
16: 1069-1072
[Full Text]
Eisenhofer, G., Walther, M. M., Huynh, T.-T., Li, S.-T., Bornstein, S. R., Vortmeyer, A., Mannelli, M., Goldstein, D. S., Linehan, W. M., Lenders, J. W. M., Pacak, K.
(2001). Pheochromocytomas in von Hippel-Lindau Syndrome and Multiple Endocrine Neoplasia Type 2 Display Distinct Biochemical and Clinical Phenotypes. J. Clin. Endocrinol. Metab.
86: 1999-2008
[Abstract][Full Text]
Salmenkivi, K., Arola, J., Voutilainen, R., Ilvesmäki, V., Haglund, C., Kahri, A. I., Heikkilä, P., Liu, J.
(2001). Inhibin/Activin {beta}B-Subunit Expression in Pheochromocytomas Favors Benign Diagnosis. J. Clin. Endocrinol. Metab.
86: 2231-2235
[Abstract][Full Text]
Plouin, P.-F., Duclos, J.-M., Soppelsa, F., Boublil, G., Chatellier, G.
(2001). Factors Associated with Perioperative Morbidity and Mortality in Patients with Pheochromocytoma: Analysis of 165 Operations at a Single Center. J. Clin. Endocrinol. Metab.
86: 1480-1486
[Abstract][Full Text]
Hirsch, N. P., Murphy, A., Radcliffe, J. J.
(2001). Neurofibromatosis: clinical presentations and anaesthetic implications. Br J Anaesth
86: 555-564
[Abstract][Full Text]
Bender, B. U., Gutsche, M., Gläsker, S., Müller, B., Kirste, G., Eng, C., Neumann, H. P. H.
(2000). Differential Genetic Alterations in von Hippel-Lindau Syndrome-Associated and Sporadic Pheochromocytomas. J. Clin. Endocrinol. Metab.
85: 4568-4574
[Abstract][Full Text]
Gimm, O., Armanios, M., Dziema, H., Neumann, H. P. H., Eng, C.
(2000). Somatic and Occult Germ-line Mutations in SDHD, a Mitochondrial Complex II Gene, in Nonfamilial Pheochromocytoma. Cancer Res.
60: 6822-6825
[Abstract][Full Text]
Eisenhofer, G., Lenders, J. W.M., Linehan, W. M., Walther, M. M., Goldstein, D. S., Keiser, H. R.
(1999). Plasma Normetanephrine and Metanephrine for Detecting Pheochromocytoma in von Hippel-Lindau Disease and Multiple Endocrine Neoplasia Type 2. NEJM
340: 1872-1879
[Abstract][Full Text]
Sandur, S., Dasgupta, A., Shapiro, J. L., Arroliga, A. C., Mehta, A. C.
(1999). Thoracic Involvement With Pheochromocytoma: A Review. Chest
115: 511-521
[Abstract][Full Text]
de Lorgeril, M., Salen, P., Martin, J.-L., Monjaud, I., Boucher, P., Mamelle, N.
(1998). Mediterranean Dietary Pattern in a Randomized Trial: Prolonged Survival and Possible Reduced Cancer Rate. Arch Intern Med
158: 1181-1187
[Abstract][Full Text]
Brauch, H., Hoeppner, W., Jahnig, H., Wohl, T., Engelhardt, D., Spelsberg, F., Ritter, M. M.
(1997). Sporadic Pheochromocytomas Are Rarely Associated with Germline Mutations in the vhl Tumor Suppressor Gene or the ret Protooncogene. J. Clin. Endocrinol. Metab.
82: 4101-4104
[Abstract][Full Text]
Plouin, P.-F., Chatellier, G., Fofol, I., Corvol, P.
(1997). Tumor Recurrence and Hypertension Persistence After Successful Pheochromocytoma Operation. Hypertension
29: 1133-1139
[Abstract][Full Text]
Neumann, H. P.H., Eng, C., Mulligan, L. M.
(1996). Von Hippel-Lindau Disease and Pheochromocytoma-Reply. JAMA
275: 840-840
[Abstract]
Neumann, H. P. H., Eng, C., Mulligan, L. M., Glavac, D., Zauner, I., Ponder, B. A. J., Crossey, P. A., Maher, E. R., Brauch, H.
(1995). Consequences of Direct Genetic Testing for Germline Mutations in the Clinical Management of Families With Multiple Endocrine Neoplasia, Type II. JAMA
274: 1149-1151
[Abstract]
Gagel, R. F., Neumann, H. P.H.
(1994). Pheochromocytoma, Multiple Endocrine Neoplasia Type 2, and von Hippel-Lindau Disease. NEJM
330: 1090-1091
[Full Text]
Hoegerle, S., Nitzsche, E., Altehoefer, C., Ghanem, N., Manz, T., Brink, I., Reincke, M., Moser, E., Neumann, H. P. H.
(2002). Pheochromocytomas: Detection with 18F DOPA Whole-Body PET3Initial Results. Radiology
222: 507-512
[Abstract][Full Text]